Onward Ho: Biocon Signals Glargine Build Up, US Biosimilars Pricing ‘Sanity’

Biocon anticipates significant US uptake of its Viatris-partnered interchangeable insulin glargine biosimilar on the back of commercial arrangements in place and expects to "move the market" in 2022.  All eyes are also on the trajectory of biosimilar insulin aspart, which received a CRL from the US FDA.